請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/46013
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 符文美 | |
dc.contributor.author | Wei-Hsun Huang | en |
dc.contributor.author | 黃韋勳 | zh_TW |
dc.date.accessioned | 2021-06-15T04:51:19Z | - |
dc.date.available | 2011-04-04 | |
dc.date.copyright | 2010-09-13 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-08-02 | |
dc.identifier.citation | Agnihotri, R., Crawford, H.C., Haro, H., Matrisian, L.M., Havrda, M.C., and Liaw, L. (2001). Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem 276, 28261-28267.
Bellahcene, A., and Castronovo, V. (1995). Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 146, 95-100. Bentzen, L., Keiding, S., Nordsmark, M., Falborg, L., Hansen, S.B., Keller, J., Nielsen, O.S., and Overgaard, J. (2003). Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiother Oncol 67, 339-344. Boyce, B.F., Yoneda, T., and Guise, T.A. (1999). Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer 6, 333-347. Brizel, D.M., Scully, S.P., Harrelson, J.M., Layfield, L.J., Bean, J.M., Prosnitz, L.R., and Dewhirst, M.W. (1996). Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56, 941-943. Brown, J.M., and Giaccia, A.J. (1998). The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58, 1408-1416. Brown, L.F., Papadopoulos-Sergiou, A., Berse, B., Manseau, E.J., Tognazzi, K., Perruzzi, C.A., Dvorak, H.F., and Senger, D.R. (1994). Osteopontin expression and distribution in human carcinomas. Am J Pathol 145, 610-623. Bussink, J., Kaanders, J.H., and van der Kogel, A.J. (2003). Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 67, 3-15. Butler, W.T. (1989). The nature and significance of osteopontin. Connect Tissue Res 23, 123-136. Chambers, A.F., Wilson, S.M., Kerkvliet, N., O'Malley, F.P., Harris, J.F., and Casson, A.G. (1996). Osteopontin expression in lung cancer. Lung Cancer 15, 311-323. Colditz, G.A., Sellers, T.A., and Trapido, E. (2006). Epidemiology - identifying the causes and preventability of cancer? Nat Rev Cancer 6, 75-83. Coleman, R.E. (1997). Skeletal complications of malignancy. Cancer 80, 1588-1594. Colla, S., Tagliaferri, S., Morandi, F., Lunghi, P., Donofrio, G., Martorana, D., Mancini, C., Lazzaretti, M., Mazzera, L., Ravanetti, L. (2007). The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. Blood 110, 4464-4475. Coppola, D., Szabo, M., Boulware, D., Muraca, P., Alsarraj, M., Chambers, A.F., and Yeatman, T.J. (2004). Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10, 184-190. Craig, A.M., Nemir, M., Mukherjee, B.B., Chambers, A.F., and Denhardt, D.T. (1988). Identification of the major phosphoprotein secreted by many rodent cell lines as 2ar/osteopontin: enhanced expression in H-ras-transformed 3T3 cells. Biochem Biophys Res Commun 157, 166-173. Cronin, P.A., Wang, J.H., and Redmond, H.P. (2010). Hypoxia increases the metastatic ability of breast cancer cells via upregulation of CXCR4. BMC Cancer 10, 225. Darash-Yahana, M., Pikarsky, E., Abramovitch, R., Zeira, E., Pal, B., Karplus, R., Beider, K., Avniel, S., Kasem, S., Galun, E. (2004). Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 18, 1240-1242. Das, R., Mahabeleshwar, G.H., and Kundu, G.C. (2004). Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J Biol Chem 279, 11051-11064. Desai, B., Rogers, M.J., and Chellaiah, M.A. (2007). Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol Cancer 6, 18. El-Tanani, M.K. (2008). Role of osteopontin in cellular signaling and metastatic phenotype. Front Biosci 13, 4276-4284. Fisher, L.W., Hawkins, G.R., Tuross, N., and Termine, J.D. (1987). Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II, and osteonectin from the mineral compartment of developing human bone. J Biol Chem 262, 9702-9708. Flynn, G., Maru, S., Loughlin, J., Romero, I.A., and Male, D. (2003). Regulation of chemokine receptor expression in human microglia and astrocytes. J Neuroimmunol 136, 84-93. Fong, Y.C., Liu, S.C., Huang, C.Y., Li, T.M., Hsu, S.F., Kao, S.T., Tsai, F.J., Chen, W.C., Chen, C.Y., and Tang, C.H. (2009). Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer 64, 263-270. Forootan, S.S., Foster, C.S., Aachi, V.R., Adamson, J., Smith, P.H., Lin, K., and Ke, Y. (2006). Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 118, 2255-2261. Franzen, A., and Heinegard, D. (1985). Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J 232, 715-724. Furger, K.A., Menon, R.K., Tuck, A.B., Bramwell, V.H., and Chambers, A.F. (2001). The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1, 621-632. Gao, C., Guo, H., Downey, L., Marroquin, C., Wei, J., and Kuo, P.C. (2003). Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis 24, 1871-1878. Giachelli, C.M., and Steitz, S. (2000). Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol 19, 615-622. Graeber, T.G., Osmanian, C., Jacks, T., Housman, D.E., Koch, C.J., Lowe, S.W., and Giaccia, A.J. (1996). Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379, 88-91. Guo, W., and Giancotti, F.G. (2004). Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5, 816-826. Hemler, M.E. (1990). VLA proteins in the integrin family: structures, functions, and their role on leukocytes. Annu Rev Immunol 8, 365-400. Hillyer, P., Mordelet, E., Flynn, G., and Male, D. (2003). Chemokines, chemokine receptors and adhesion molecules on different human endothelia: discriminating the tissue-specific functions that affect leucocyte migration. Clin Exp Immunol 134, 431-441. Hwang, S.M., Wilson, P.D., Laskin, J.D., and Denhardt, D.T. (1994). Age and development-related changes in osteopontin and nitric oxide synthase mRNA levels in human kidney proximal tubule epithelial cells: contrasting responses to hypoxia and reoxygenation. J Cell Physiol 160, 61-68. Jacob, K., Webber, M., Benayahu, D., and Kleinman, H.K. (1999). Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res 59, 4453-4457. Jain, A., McKnight, D.A., Fisher, L.W., Humphreys, E.B., Mangold, L.A., Partin, A.W., and Fedarko, N.S. (2009). Small integrin-binding proteins as serum markers for prostate cancer detection. Clin Cancer Res 15, 5199-5207. Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R.C., Ghafoor, A., Feuer, E.J., and Thun, M.J. (2005). Cancer statistics, 2005. CA Cancer J Clin 55, 10-30. Kaelin, W.G., Jr., and Ratcliffe, P.J. (2008). Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30, 393-402. Kanaya, K., and Kamitani, T. (2003). pVHL-independent ubiquitination of HIF1alpha and its stabilization by cobalt ion. Biochem Biophys Res Commun 306, 750-755. Le, Q.T., Sutphin, P.D., Raychaudhuri, S., Yu, S.C., Terris, D.J., Lin, H.S., Lum, B., Pinto, H.A., Koong, A.C., and Giaccia, A.J. (2003). Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9, 59-67. Liaw, L., Birk, D.E., Ballas, C.B., Whitsitt, J.S., Davidson, J.M., and Hogan, B.L. (1998). Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest 101, 1468-1478. Lin, Y.T., Tang, C.H., Chuang, W.J., Wang, S.M., Huang, T.F., and Fu, W.M. (2005). Inhibition of adipogenesis by RGD-dependent disintegrin. Biochem Pharmacol 70, 1469-1478. Lopez, C.A., Olson, E.S., Adams, J.C., Mou, K., Denhardt, D.T., and Davis, R.L. (1995). Osteopontin expression detected in adult cochleae and inner ear fluids. Hear Res 85, 210-222. Ma, C., Rong, Y., Radiloff, D.R., Datto, M.B., Centeno, B., Bao, S., Cheng, A.W., Lin, F., Jiang, S., Yeatman, T.J. (2008). Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev 22, 308-321. Miranti, C.K., and Brugge, J.S. (2002). Sensing the environment: a historical perspective on integrin signal transduction. Nat Cell Biol 4, E83-90. Moehler, T.M., Ho, A.D., Goldschmidt, H., and Barlogie, B. (2003). Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol 45, 227-244. Moeller, B.J., Cao, Y., Li, C.Y., and Dewhirst, M.W. (2004). Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5, 429-441. Mueller-Klieser, W., Vaupel, P., Manz, R., and Schmidseder, R. (1981). Intracapillary oxyhemoglobin saturation of malignant tumors in humans. Int J Radiat Oncol Biol Phys 7, 1397-1404. Nemir, M., Bhattacharyya, D., Li, X., Singh, K., Mukherjee, A.B., and Mukherjee, B.B. (2000). Targeted inhibition of osteopontin expression in the mammary gland causes abnormal morphogenesis and lactation deficiency. J Biol Chem 275, 969-976. Nguyen, D.X., Bos, P.D., and Massague, J. (2009). Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9, 274-284. Oh, W.K., and Kantoff, P.W. (1998). Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 160, 1220-1229. Oldberg, A., Franzen, A., and Heinegard, D. (1986). Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A 83, 8819-8823. Padera, T.P., Stoll, B.R., Tooredman, J.B., Capen, D., di Tomaso, E., and Jain, R.K. (2004). Pathology: cancer cells compress intratumour vessels. Nature 427, 695. Pfaff, M., Tangemann, K., Muller, B., Gurrath, M., Muller, G., Kessler, H., Timpl, R., and Engel, J. (1994). Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. J Biol Chem 269, 20233-20238. Prince, C.W., and Butler, W.T. (1987). 1,25-Dihydroxyvitamin D3 regulates the biosynthesis of osteopontin, a bone-derived cell attachment protein, in clonal osteoblast-like osteosarcoma cells. Coll Relat Res 7, 305-313. Rangaswami, H., Bulbule, A., and Kundu, G.C. (2006). Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16, 79-87. Ritchie, C.K., Giordano, A., and Khalili, K. (2000). Integrin involvement in glioblastoma multiforme: possible regulation by NF-kappaB. J Cell Physiol 184, 214-221. Rittling, S.R., and Chambers, A.F. (2004). Role of osteopontin in tumour progression. Br J Cancer 90, 1877-1881. Rittling, S.R., and Novick, K.E. (1997). Osteopontin expression in mammary gland development and tumorigenesis. Cell Growth Differ 8, 1061-1069. Ross, F.P., Chappel, J., Alvarez, J.I., Sander, D., Butler, W.T., Farach-Carson, M.C., Mintz, K.A., Robey, P.G., Teitelbaum, S.L., and Cheresh, D.A. (1993). Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J Biol Chem 268, 9901-9907. Said, H.M., Katzer, A., Flentje, M., and Vordermark, D. (2005). Response of the plasma hypoxia marker osteopontin to in vitro hypoxia in human tumor cells. Radiother Oncol 76, 200-205. Senger, D.R., Perruzzi, C.A., Gracey, C.F., Papadopoulos, A., and Tenen, D.G. (1988). Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res 48, 5770-5774. Senger, D.R., Wirth, D.F., and Hynes, R.O. (1979). Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 16, 885-893. Sodek, J., Ganss, B., and McKee, M.D. (2000). Osteopontin. Crit Rev Oral Biol Med 11, 279-303. Standal, T., Borset, M., and Sundan, A. (2004). Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26, 179-184. Sun, X., Wei, L., Chen, Q., and Terek, R.M. (2010). CXCR4/SDF1 mediate hypoxia induced chondrosarcoma cell invasion through ERK signaling and increased MMP1 expression. Mol Cancer 9, 17. Sutherland, R.M. (1988). Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 240, 177-184. Swenson, S., Ramu, S., and Markland, F.S. (2007). Anti-angiogenesis and RGD-containing snake venom disintegrins. Curr Pharm Des 13, 2860-2871. Taichman, R.S., Cooper, C., Keller, E.T., Pienta, K.J., Taichman, N.S., and McCauley, L.K. (2002). Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62, 1832-1837. Takahashi, K., Stamenkovic, I., Cutler, M., Saya, H., and Tanabe, K.K. (1995). CD44 hyaluronate binding influences growth kinetics and tumorigenicity of human colon carcinomas. Oncogene 11, 2223-2232. Teitelbaum, S.L., and Ross, F.P. (1994). Mechanisms of tumor-induced osteolysis. Lab Invest 71, 453-455. Teramoto, H., Castellone, M.D., Malek, R.L., Letwin, N., Frank, B., Gutkind, J.S., and Lee, N.H. (2005). Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12. Oncogene 24, 489-501. Tredan, O., Galmarini, C.M., Patel, K., and Tannock, I.F. (2007). Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99, 1441-1454. Tsuchiya, Y., Sawada, S., Tsukada, K., and Saiki, I. (2002). A new pseudo-peptide of Arg-Gly-Asp (RGD) inhibits intrahepatic metastasis of orthotopically implanted murine hepatocellular carcinoma. Int J Oncol 20, 319-324. Tuck, A.B., and Chambers, A.F. (2001). The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 6, 419-429. van der, P., Vloedgraven, H., Papapoulos, S., Lowick, C., Grzesik, W., Kerr, J., and Robey, P.G. (1997). Attachment characteristics and involvement of integrins in adhesion of breast cancer cell lines to extracellular bone matrix components. Lab Invest 77, 665-675. Varner, J.A., and Cheresh, D.A. (1996). Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Important Adv Oncol, 69-87. Vaupel, P., Kelleher, D.K., and Hockel, M. (2001). Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 28, 29-35. Wai, P.Y., and Kuo, P.C. (2004). The role of Osteopontin in tumor metastasis. J Surg Res 121, 228-241. Wai, P.Y., and Kuo, P.C. (2008). Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 27, 103-118. Wang, X., Li, C., Chen, Y., Hao, Y., Zhou, W., Chen, C., and Yu, Z. (2008). Hypoxia enhances CXCR4 expression favoring microglia migration via HIF-1alpha activation. Biochem Biophys Res Commun 371, 283-288. Weber, G.F. (2001). The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 1552, 61-85. Whitmore, W.F., Jr. (1984). Natural history and staging of prostate cancer. Urol Clin North Am 11, 205-220. Yamate, T., Mocharla, H., Taguchi, Y., Igietseme, J.U., Manolagas, S.C., and Abe, E. (1997). Osteopontin expression by osteoclast and osteoblast progenitors in the murine bone marrow: demonstration of its requirement for osteoclastogenesis and its increase after ovariectomy. Endocrinology 138, 3047-3055. Yang, R.S., Tang, C.H., Chuang, W.J., Huang, T.H., Peng, H.C., Huang, T.F., and Fu, W.M. (2005). Inhibition of tumor formation by snake venom disintegrin. Toxicon 45, 661-669. Yeh, C.H., Peng, H.C., Yang, R.S., and Huang, T.F. (2001). Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells. Mol Pharmacol 59, 1333-1342. Yeh, W.L., Lu, D.Y., Lee, M.J., and Fu, W.M. (2009). Leptin induces migration and invasion of glioma cells through MMP-13 production. Glia 57, 454-464. Yuan, Y., Hilliard, G., Ferguson, T., and Millhorn, D.E. (2003). Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J Biol Chem 278, 15911-15916. Yun, Z., Menter, D.G., and Nicolson, G.L. (1996). Involvement of integrin alphavbeta3 in cell adhesion, motility, and liver metastasis of murine RAW117 large cell lymphoma. Cancer Res 56, 3103-3111. Zhu, Y., Denhardt, D.T., Cao, H., Sutphin, P.D., Koong, A.C., Giaccia, A.J., and Le, Q.T. (2005). Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene 24, 6555-6563. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/46013 | - |
dc.description.abstract | 癌症的轉移是造成病情惡化以及導致治療失敗的主要原因,而癌細胞進行轉移首先會侵犯周圍的組織,之後再進一步的跟隨循環系統到達新的組織,這步驟之中是由許多調控因子和一連串複雜的訊息傳遞所組成的。攝護腺癌是造成男性跟癌症相關死亡排名的第二位,因攝護腺癌而死亡的病人有超過85%的有伴隨著骨頭轉移的情形。骨調素(Osteopontin) 是一種高度磷酸化和醣化的分泌型蛋白質,參與很多不同的生理功能,在先前的研究中也指出骨調素在癌症的侵入以及轉移中扮演了重要的角色。如果在癌症病人體內的骨調素有不正常增加表現的情形發生時,往往代表病人有較差的預後以及較低的存活率。而癌症的微環境常因為癌細胞的過度增生而呈現缺氧的情形,癌細胞在此環境之中會增加其侵入性以及轉移的能力。在本篇的研究當中發現在缺氧環境下或給予一種誘發化學性缺氧的化合物CoCl2,攝護腺癌細胞PC-3的骨調素mRNA以及蛋白表現有增加的情形,並且透過免疫螢光染色的方法也觀察到在缺氧環境下攝護腺癌細胞膜的周圍以及細胞質當中增加了骨調素的表現,之後更進一步的去檢視究竟增加骨調素的表現會不會影響細胞遷移(migration)的能力,研究結果顯示在缺氧環境之下會增加PC-3細胞遷移的能力,而這增加的情形會在減少骨調素基因表現的PC-3細胞中同樣的有被抑制。先前的研究中有提到骨調素影響癌細胞的遷移是透過其受體αvβ3 integrin,因此在我們的研究中利用αvβ3 integrin的抗體有顯著的抑制缺氧環境所促進癌細胞遷移的情形,這樣的結果指出αvβ3 integrin參與了攝護腺癌細胞的遷移行為。此外我們更進一步利用從Rhodostomin之中改變RGD domain所獲得的衍生物,並且結合了C34S-HSA來避免HSA蛋白發生dimmer情形的αvβ3-selective disintegrin HSA(C34S)-ARLDDL,發現此disintegrin有抑制癌細胞缺氧下所促進的遷移以及侵入(invasion)的情形。這些結果顯示αvβ3在缺氧下促進遷移和侵入行為中扮演著重要的角色。然而無論是αvβ3的抗體或是disintegrin都無法完全的抑制缺氧環境下所促進癌細胞遷移的能力,因此可能有其他的調控因子參與,而在先前的研究中指出趨化素受體(chemokine receptor)也參與了癌症的轉移,因此檢視了並發現在缺氧環境之下CXCR4蛋白表現有增加,並且這增加的CXCR4的表現會更進一步的促進攝護腺癌細胞遷移至其配體SDF-1α,並且在缺氧環境之下給與CXCR4抑制劑AMD3100也同樣的抑制了其遷移的能力。
總結本篇的研究發現在缺氧的環境之下有增加攝護腺癌細胞的骨調素表現並且參與了缺氧下所促進遷移的能力,並且更進一步的提供了disintegrin中帶有RGD-containing或是類似物可以用來做為癌症治療的候選藥物。 | zh_TW |
dc.description.abstract | Tumor invasion and metastasis consist of multiple and complicated processes, which are the main cause of therapeutic failure and death for cancer patients. Prostate cancer is the second leading cause of cancer-related deaths in males. More than 85% of those who die of prostate carcinoma have bone metastases. Osteopontin (OPN), a secreted glycosylated phosphoprotein, is abundantly expressed in bone matrix and is involved in numerous physiological functions and associated with the late stage of various cancers. OPN plays an important role in metastatic and invasive ability of tumor cells. Increase of osteopontin expression in cancer patients is associated with poor outcome and low survival rate. Hypoxia is also an important factor to decrease the effectiveness of conventional chemotherapy and radiotherapy. In the present study, it was found that the mRNA and protein expression levels of osteopontin were upregulated by hypoxia or CoCl2 treatment. Immunofluorescence analysis also indicated that OPN expression was upregulated around the cell membrane and the cytoplasm after exposure to hypoxia. ROS was involved in the hypoxia-induced OPN expression. We thus further examined whether OPN influenced the migration ability of PC-3 cells. It was found that hypoxia treatment increased the migration of PC-3 cells and osteopontin knockdown antagonized the hypoxia-induced migration activity. Previous reports have shown that osteopontin affects cell migration through its receptor αvβ3 integrin. In our study, it was found that αvβ3 integrin antibody markedly inhibited hypoxia-induced tumor cell migration, indicating the involvement of αvβ3 integrin in hypoxia-induced migration activity. In addition, we used an αvβ3-selective disintegrin HSA(C34S)-ARLDDL, which is derived from the mutation of neighborhood of RGD domain of Rhodostomin and is modified to prevent HSA protein dimmer formation by conjugation with C34S-HSA. It was found that HSA(C34S)-ARLDDL also antagonized hypoxia-induced migration and invasion activity. The results indicate that αvβ3 plays an important role in hypoxia-induced migration and invasion. Since αvβ3 integrin monoclonal antibody or disintegrin cannot completely inhibit hypoxia-induced cancer cell migration, other factors may be involved in hypoxia-induced action. It has been previously shown that chemokine receptors participate in tumor metastasis. We thus further examined the chemokine receptor expression in hypoxia condition and found that CXCR4 was upregulated by hypoxia treatment. It was also found that hypoxia-induced CXCR4 expression increased the migration activity toward its ligand SDF-1α and CXCR4 inhibitor AMD3100 antagonized hypoxia-induced migration activities.
In conclusion, we found that osteopontin was upregulated by hypoxia treatment and was involved in hypoxia-induced migration of prostate cancer cell line. Moreover, we also provide the evidence that RGD-containing or mimetics of disintegrin is a potential therapeutic drug candidate for cancer treatment. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T04:51:19Z (GMT). No. of bitstreams: 1 ntu-99-R97443021-1.pdf: 2837393 bytes, checksum: 1f778884ff91fc6462c168eae879f757 (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 目 錄
Abbreviations V 摘要 VII Abstract IX Chapter 1 Introduction 1 1-1 Prostate cancer 1 1-2 Tumor invasion and metastasis 2 1-3 Integrin and disintegrin 4 1-4 Hypoxia 6 1-5 Osteopontin 9 Chapter 2 Materials and Methods 24 Chapter 3 Results 30 3-1. Effect of cobalt chloride on osteopontin mRNA expression in prostate cancer cell line. 30 3-2. Cobalt chloride increases osteopontin protein expression. 31 3-3. Effect of hypoxia on osteopontin mRNA in prostate cancer cell line. 31 3-4. Effect of hypoxia on osteopontin protein expression in prostate cancer cells. 32 3-5. Osteopontin increases after hypoxia treatment in PC-3 cells by immunofluorescence staining 32 3-6. Role of reactive oxygen species, p38 MAPK and Akt in CoCl2-induced osteopontin expression. 33 3-7. Effect of hypoxia and osteopontin knockdown on the migration of prostate cancer cells. 34 3-8. αvβ3 integrin is involved in hypoxia-induced cancer cell migration. 35 3-9. Effect of hypoxia and disintegrin on the invasion of prostate cancer cells. 35 3-10. Effect of hypoxia on endogenous chemokine receptor CXCR4 protein expression in prostate cancer cell line. 36 3-11. Exposure to hypoxia enhances SDF-1α-dependent cell migration. 37 3-12. Effect of CXCR4 inhibition on the hypoxia-induced migration of prostate cancer cells. 37 Chapter 4 Discussion 39 References 61 圖 目 錄 Figure 1-2-1. The metastatic cascade. 15 Figure 1-3-1. The integrin family. 16 Figure 1-3-2. Integrin–receptor-tyrosine-kinase signalling induces cell migration and invasion. 17 Figure 1-4-1. The characteristics of a hypoxic tumour mass. 18 Figure 1-4-2. The role of hypoxia in the hallmarks of human cancer. 19 Figure 1-4-3. HIF-induced gene products and their function. 20 Figure 1-5-1. Schematic representation of the domain structure of osteopontin (OPN). 21 Figure 1-5-2. Molecular mechanism of osteopontin (OPN)-induced tumor growth and metastasis through αvβ3 integrin/CD44-mediated pathways. 22 Figure 1-5-3. Schematic depiction of metastatic mechanisms in the setting of colon cancer. 23 Figure 1. Time-dependent increase of osteopontin mRNA expression by CoCl2 in PC-3 cells. 46 Figure 2. Increase of osteopontin protein expression by CoCl2 in PC-3 cells. 47 Figure 3. Increase of osteopontin mRNA levels by hypoxia in PC-3 human prostate cancer cells. 48 Figure 4. Increase of osteopontin protein levels by hypoxia in PC-3 human prostate cancer cells. 49 Figure 5. Osteopontin increases after hypoxia treatment in PC-3 cells by immunofluorescent staining. 50 Figure 6. Reactive oxygen species are involved in CoCl2 –induced osteopontin production in PC-3 prostate cancer cells. 51 Figure 7. Involvement of p38 and Akt in CoCl2-induced osteopontin protein expression. 52 Figure 8. Phosphorylation of Akt protein by CoCl2 treatment. 53 Figure 9. Osteopontin is involved in hypoxia-induced migration in PC-3 cells. 54 Figure 10. Hypoxia-induced migration activity is antagonized by αvβ3 integrin antagonist in PC-3 cells. 55 Figure 11. Hypoxia-induced invasion activity is antagonized by αvβ3 integrin antagonist in PC-3 cells. 56 Figure 12. Increase of chemokine receptor CXCR4 protein expression by hypoxia in PC-3 cells. 57 Figure 13. Increase of cell migration toward SDF-1α in hypoxia in PC-3 cells 58 Figure 14. Hypoxia-induced migration activity is attenuated by CXCR4 receptor antagonist in PC-3 cells. 59 Figure 15. Osteopontin and CXCR4 are involved in hypoxia-induced tumor cell migration 60 | |
dc.language.iso | en | |
dc.title | 攝護腺癌細胞在缺氧環境下調節osteopontin表現之研究 | zh_TW |
dc.title | Regulation of osteopontin expression by hypoxia in prostate cancer cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 楊春茂,林琬琬,劉興華 | |
dc.subject.keyword | osteopontin,hypoxia,prostate cancer,integrin,disintegrin, | zh_TW |
dc.relation.page | 67 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2010-08-02 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 2.77 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。